Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value

Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 14th May, paid: 10th Jul more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -1.7%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2013, GlaxoSmithKline plc revenues increased less than 1% to L26.51B. Net income increased 21% to L5.44B. Revenues reflect Pharmaceuticals segment increase of less than 1% to L21.32B, Consumer Healthcare segment increase of less than 1% to L5.19B, USA segment increase of 3% to L7.19B, Europe segment increase of 3% to L5.17B, Other trading segment increase of 2% to L1.22B. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

Recent History
Latest interim period (ended 31st Dec '13) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: 1,798 (+9.61% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +6.6% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
29 brokers Broker Consensus Trend
Broker Recommendations for GlaxoSmithKline
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 3 20 3 3

Named Brokers and Analysts
Jefferies & Company, Inc. Jeffrey Holford , Credit Suisse Kerry Holford , Leerink Partners LLC Seamus Fernandez , Sanford Bernstein Tim Anderson , Bank Vontobel AG , First Global Kavita Thomas , Nomura Securities , Jefferies International Ltd , Seymour Pierce , Panmure Gordon Savvas Neophytou , Natixis Philippe Lanone Beatrice Muzard , Collins Stewart & Co , Davy , CA Cheuvreux Marcel Brand , Macquarie Research , Societe Generale Stephen McGarry , Erste Bank Stephan Lingnau , WestLB Equity Markets , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Hamburger Sparkasse (HASPA) Marco Gunther , Kepler Cheuvreux Fabian Wenner, PhD , Charles Stanley Rae Ellingham , Cenkos Securities Navid Malik , Raymond James Euro Equities , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Matrix Corporate Capital LLP , Liberum Naresh Chouhan , Alphavalue Armelle Moulin ,

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Directors: Andrew Witty (CEO) 48, Simon Dingemans (CFO) 49, Moncef Slaoui (Corp. Exec.) 53, Deirdre Connelly (Corp. Exec.) , Roger Connor (Corp. Exec.) , Marc Dunoyer (Corp. Exec.) , Shah Abbas Hussain (Corp. Exec.) 47, Patrick Vallance (Corp. Exec.) , Emma Walmsley (Corp. Exec.) , Christophe Weber (Corp. Exec.) ,

No. of Employees: 99,817 No. of Shareholders: 142,145

Last Annual December 31st, 2013
Last Interim December 31st, 2013
Shares in Issue 4,859,290,389
Free Float 4.79bn (98.5%)
ISIN GB0009252882

Address C8 Gsk House 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom
Phone +44 20 80475000
Contact David Mawdsley (Director of Investor Relations)
Auditors PricewaterhouseCoopers LLP

GSK Share Price Performance GSK Quote
2.5  0.2%
Traded 5:14pm · Minimum 15 min delayed · NMS: 1.000k

Latest GSK News Announcements (delayed)

Upcoming GSK Events
Wednesday 30th April, 2014
Q1 2014 GlaxoSmithKline PLC Earnings Release
Wednesday 7th May, 2014
GlaxoSmithKline PLC Annual General Meeting
Wednesday 23rd July, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Release
Wednesday 22nd October, 2014
Q3 2014 GlaxoSmithKline PLC Earnings Release

Recent ↓
Tuesday 22nd April, 2014
GlaxoSmithKline PLC major transaction with Novartis Afternoon Conference Call (Investors/Analysts)
Tuesday 22nd April, 2014
GlaxoSmithKline PLC major transaction with Novartis Morning Conference Call (Investors/Analysts)
Tuesday 22nd April, 2014
GlaxoSmithKline PLC major transaction with Novartis Conference Call (Media)
Monday 31st March, 2014
Macquarie India Pharmaceutical Tour - Mumbai
Tuesday 4th March, 2014
GlaxoSmithKline at Cowen Health Care Conference
Tuesday 4th March, 2014
GlaxoSmithKline at Credit Suisse Healthcare Conference
Monday 24th February, 2014
GlaxoSmithKline at Citi Global Healthcare Conference
Wednesday 19th February, 2014
Dividend For GSK.L
Wednesday 19th February, 2014
Dividend For GSK
Wednesday 19th February, 2014
Dividend For GSK.BA

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.

Should you buy GSK

Access GSK Analytics Now!